79615-79-5

Basic information

• Product Name: Ethanone, 1-[3-[(4-chlorophenyl)methoxy]phenyl]-
• CAS NO: 79615-79-5
• Molecular Formula: C15H13ClO2
• Molecular Weight: 260.72
• Mol File: 79615-79-5.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: Ethanone, 1-[3-[(4-chlorophenyl)methoxy]phenyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 1-[3-[(4-chlorophenyl)methoxy]phenyl]-(79615-79-5)
• EPA Substance Registry System: Ethanone, 1-[3-[(4-chlorophenyl)methoxy]phenyl]-(79615-79-5)

Safety Data

• Hazardous Substances Data: 79615-79-5(Hazardous Substances Data)

Upstream product

• 121-71-1 3-Hydroxyacetophenone 
• 873-76-7 para-Chlorobenzyl alcohol 
• 622-95-7 4-chlorobenzyl bromide 
• 104-83-6 1-Chloro-4-(chloromethyl)benzene 

Downstream Products

• 79615-65-9 4-[3-(4-Chloro-benzyloxy)-phenyl]-thiazol-2-ylamine; hydrochloride 
• 77175-44-1 1-{1-[3-(4-Chloro-benzyloxy)-phenyl]-vinyl}-1H-imidazole 
• 108649-41-8 C₂₁H₁₉ClN₄O 
• 79615-98-8 2-Chloro-1-[3-(4-chloro-benzyloxy)-phenyl]-ethanone 

Relevant articles and documents

Neuroprotective effects of benzyloxy substituted small molecule monoamine oxidase B inhibitors in Parkinson's disease

The benzyloxy substituted small molecules are well-known highly potent monoamine oxidase B inhibitors, but their therapeutic potential against Parkinson's disease have not been investigated in detail. In this paper, a series of representative benzyloxy substituted derivatives were synthesized and evaluated for MAO-A/B inhibition. In addition, their neuroprotective effects were investigated in 6-OHDA- and rotenone-treated PC12 cells. It was observed that most of the compounds exhibited a marked increase in survival of PC12 cells which treated with the neurotoxins. Among them, 13 exhibited remarkable and balanced neuroprotective potency. The protective effects of 13 against neurotoxins-induced apoptosis were confirmed with flow cytometry and staining methods. Furthermore, 13 also showed good BBB permeability and low toxicity according to in vitro BBB prediction and in vivo acute toxicity test. The results indicated that 13 is an effective and promising candidate to be further developed as disease-modifying drug for Parkinson's disease therapy.

Effects of the aryl linker and the aromatic substituent on the anti-HCV activities of aryl diketoacid (ADK) analogues

Based on our pharmacophore model of the aryl diketoacids (ADKs), we designed and prepared a series of novel ADK analogues, which showed potent inhibitory activities against the NS5B polymerase in the submicromolar range. Pharmacophore-guided docking study revealed that the antiviral activities of the ADKs are highly dependent upon the aryl linker as well as the size and position of the aromatic substituent. It is of another importance that, unlike previously reported ADKs, three ADK analogues synthesized in this study effectively blocked Hepatitis C Virus (HCV) replication in the replicon systems.